Previous studies found that serum LDH was able to distinguish renal cell carcinoma patients who were more likely to benefit from TORC1 inhibition temsirolimus (47), and identify locally advanced cervical cancer patients who could take advantage of neoadjuvant chemotherapy (37). The gene discussed is CRTC1; the disease is hereditary clear cell renal cell carcinoma.